UDP-glucuronosyltransferase 1A10: Activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility

Drug Metabolism and Disposition

Volumn 38, Issue 3, 2010, Pages 484-490

  Balliet, Rene M ^a,b   Chen, Gang ^b   Dellinger, Ryan W ^a,b   Lazarus, Philip ^a,b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A10; LUCIFERASE;

ARTICLE; BASE PAIRING; CANCER SUSCEPTIBILITY; CAUCASIAN; CELL FREE SYSTEM; CONTROLLED STUDY; ENZYME ACTIVITY; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; GLUCURONIDATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEGRO; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

CACO-2 CELLS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENES, REPORTER; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOMIC STRUCTURAL VARIATION; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; LIVER NEOPLASMS; METABOLIC DETOXICATION, PHASE II; NITROSAMINES; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PYRIDINES; SEQUENCE DELETION;

NICOTIANA TABACUM;

EID: 76749113441     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030569     Document Type: Article

References (37)

1. Basu NK, Kubota S, Meselhy MR, Ciotti M, Chowdhury B, Hartori M, and Owens IS (2004) Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. J Biol Chem 279:28320-28329.
2. Beaulieu M, Lévesque E, Hum DW, and Bélanger A (1998) Isolation and characterization of a human orphan UDP-glucuronosyltransferase, UGT2B11. Biochem Biophys Res Commun 248:44-50.
3. Beaulieu M, Lévesque E, Tchernof A, Beatty BG, Belanger A, and Hum DW (1997) Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme. DNA Cell Biol 16:1143-1154.
4. Bélanger A, Hum DW, Beaulieu M, Lévesque E, Guillemette C, Tchernof A, Bélanger G, Turgeon D, and Dubois S (1998) Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. J Steroid Biochem Mol Biol 65:301-310.
5. Burchell B and Hume R (1999) Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol 14:960-966.
6. Carrier JS, Turgeon D, Journault K, Hum DW, and Bélanger A (2000) Isolation and characterization of the human UGT2B7 gene. Biochem Biophys Res Commun 272:616-621.
7. Chen G, Dellinger RW, Sun D, Spratt TE, and Lazarus P (2008) Glucuronidation of tobacco-specific nitrosamines by UGT2B10. Drug Metab Dispos 36:824-830.
8. Ciotti M, Obaray R, Martín MG, and Owens IS (1997) Genetic defects at the UGT1 locus associated with Crigler-Najjar type I disease, including a prenatal diagnosis. Am J Med Genet 68:173-178.
9. Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, and Lazarus P (2007) Glucuronidation of PhIP and N-OH-PhIP by UDP- glucuronosyltransferase 1A10. Carcinogenesis 28:2412-2418.
10. Dellinger RW, Fang JL, Chen G, Weinberg R, and Lazarus P (2006) Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos 34:943-949.
11. Elahi A, Bendaly J, Zheng Z, Muscat JE, Richie JP Jr, Schantz SP, and Lazarus P (2003) Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 98:872-880.
12. Elahi A, Zheng Z, Park J, Eyring K, McCaffrey T, and Lazarus P (2002) The human OGG1 DNA repair enzyme and its association with orolaryngeal cancer risk. Carcinogenesis 23:1229-1234.
13. Fang JL, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, and Lazarus P (2002) Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res 62:1978-1986.
14. Gregory PA, Lewinsky RH, Gardner-Stephen DA, and Mackenzie PI (2004a) Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 genes by hepatocyte nuclear factor 1alpha and the caudal-related homeodomain protein 2. Mol Pharmacol 65:953-963.
15. Gregory PA, Lewinsky RH, Gardner-Stephen DA, and Mackenzie PI (2004b) Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 199:354-363.
16. Guéraud F and Paris A (1998) Glucuronidation: a dual control. Gen Pharmacol 31:683-688.
17. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, and Housman DE (2000) Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10:629-644.
18. Jin C, Miners JO, Lillywhite KJ, and Mackenzie PI (1993) Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 264:475-479.
19. Kubota T, Lewis BC, Elliot DJ, Mackenzie PI, and Miners JO (2007) Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4. Mol Pharmacol 72:1054-1062.
20. Lazarus P, Zheng Y, Aaron Runkle E, Muscat JE, and Wiener D (2005) Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genomics 15:769-778.
21. Lévesque E, Beaulieu M, Green MD, Tephly TR, Bélanger A, and Hum DW (1997) Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 7:317-325.
22. Nagar S and Remmel RP (2006) Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25:1659-1672.
23. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, and Yokoi T (2008) Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461-1464.
24. Oguri T, Takahashi T, Miyazaki M, Isobe T, Kohno N, Mackenzie PI, and Fujiwara Y (2004) UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res 24:2893-2896.
25. Owens IS and Ritter JK (1995) Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. Prog Nucleic Acid Res Mol Biol 51:305-338.
26. Park JY, Schantz SP, Stern JC, Kaur T, and Lazarus P (1999) Association between glutathione S-transferase pi genetic polymorphisms and oral cancer risk. Pharmacogenetics 9:497-504.
27. Ren Q, Murphy SE, Zheng Z, and Lazarus P (2000) O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 28:1352-1360.
28. Richie JP Jr, Carmella SG, Muscat JE, Scott DG, Akerkar SA, and Hecht SS (1997) Differences in the urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in black and white smokers. Cancer Epidemiol Biomarkers Prev 6:783-790.
29. Ritter JK, Chen F, Sheen YY, Tran HM, Kimura S, Yeatman MT, and Owens IS (1992) A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 267:3257-3261.
30. Starlard-Davenport A, Lyn-Cook B, and Radominska-Pandya A (2008) Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene. Steroids 73:139-147.
31. Strassburg CP, Oldhafer K, Manns MP, and Tukey RH (1997) Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212-220.
32. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, and Lazarus P (2006) Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 8:R50.
33. Tephly TR and Burchell B (1990) UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends Pharmacol Sci 11:276-279.
34. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
35. Wiener D, Doerge DR, Fang JL, Upadhyaya P, and Lazarus P (2004a) Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos 32:72-79.
36. Wiener D, Fang JL, Dossett N, and Lazarus P (2004b) Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone glucuronidation phenotype in human liver microsomes. Cancer Res 64:1190-1196.
37. Zheng Z, Fang JL, and Lazarus P (2002) Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 30:397-403.